BNC signs eighth nanotech product development contract

Published: 23-Jan-2009

Bio Nano Consulting (BNC), a UK-based bio-nanotechnology product development consultancy, has signed a collaborative agreement with a Top 5 pharma company to develop new assay systems for its product discovery and development.


Bio Nano Consulting (BNC), a UK-based bio-nanotechnology product development consultancy, has signed a collaborative agreement with a Top 5 pharma company to develop new assay systems for its product discovery and development.

The agreement is the eighth major contract won by BNC in 2008, and follows the completion last December of a second contract with Targanta Therapeutics, in which BNC used cantilever-array assay system technology to analyse the mechanism of action of Targanta's novel lipoglycopeptide antibiotic, oritavancin.

Commenting on the new contract, Dr David Sarphie, chief executive of Bio Nano Consulting, said: "Nanotechnology is finding more applications in industry, and BNC is developing a reputation within the pharmaceutical, biotech, medtech and healthcare industries for providing novel approaches in research and development.

'With the unparalleled expertise of scientists at University College London's centre for nanotechnology, the Institute of Biomedical Engineering at Imperial College and the National Physical Laboratory, BNC is ideally placed to offer nanotechnology solutions in these sectors."

You may also like